115 completed, 32 terminated, 10 recruiting, 9 unknown. 172 Phase 2, 50 Phase 1, 2 Phase 3.
Follow Non-Hodgkin's Lymphoma: new trials by email Literature Review of Non-Hodgkin's Lymphoma trials Research Report on Non-Hodgkin's Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BEX101 in B-cell Non-Hodgkin's Lymphoma BEX101 injection - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-10-15 | 2026-10-22 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) Intravenous immunoglobulin, Trimethoprim / Sulfamethoxazole, Amoxicillin clavulanic acid - Myeloma, Non-Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-05-06 | 2025-10-07 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies GNC-035 - Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 40 | 2023-11-01 | 2026-08-27 |
| A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL MBS303 - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Mabworks Biotech Co., Ltd. | 132 | 2023-06-28 | 2024-11-20 |
| Cord Blood Transplant in Adults With Blood Cancers Conditioning Chemotherapy, Cord blood graft - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 17 | 2023-05-22 | 2026-10-23 |
| A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma GNC-038 - Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 40 | 2022-09-26 | 2026-08-27 |
| Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma single dose of CNCT19 - Non-Hodgkin's Lymphoma | Phase 2 | Recruiting | Juventas Cell Therapy Ltd. | 60 | 2020-10-26 | 2025-02-07 |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Copanlisib, Rituximab, Bendamustine - Lymphoid Leukemia, Non-Hodgkin's Lymphoma | Phase 2 | Terminated | University of Washington | 1 | 2020-01-31 | 2022-04-11 |
| CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies CLIC-1901 - Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Recruiting | Ottawa Hospital Research Institute | 60 | 2019-10-16 | 2025-08-14 |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma Rituximab, Copanlisib, Bone Marrow Aspiration/Biopsy - Follicular Lymphoma, Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2019-08-22 | 2026-03-03 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma DA-EPOCH, Rituximab, CHOP - Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2019-08-05 | 2026-10-26 |
| Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Chiauranib, Chidamide - Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Chipscreen Biosciences, Ltd. | 9 | 2019-07-11 | 2022-03-09 |
| Vaccination With Flt3L, Radiation, and Poly-ICLC Pembrolizumab, Flt3L, Radiation - Non-Hodgkin's Lymphoma, Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 17 | 2019-04-05 | 2026-05-22 |
| MB-CART20.1 Lymphoma MB-CART20.1 - Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | Miltenyi Biomedicine GmbH | 10 | 2018-09-25 | 2024-11-21 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2018-02-20 | 2026-08-18 |
| Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Hematopoietic Cell Transplantation, Tbo-filgrastim, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Plasma Cell Myeloma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 77 | 2017-10-12 | 2025-12-17 |
| Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma TQB2303, Rituximab - Non-hodgkin's Lymphoma | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 122 | 2017-05-01 | 2018-03-07 |
| Allo HSCT Using RIC for Hematological Diseases Allopurinol, Fludarabine, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 156 | 2017-03-09 | 2023-09-21 |
| A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma Glofitamab, Obinutuzumab, Tocilizumab - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 940 | 2017-02-21 | 2026-10-28 |
Showing 20 of 172. Sign in to see all of them.
Lymphoma, Non-Hodgkin (172) · Hodgkin Disease (39) · Lymphoma (39) · Multiple Myeloma (26) · Myelodysplastic Syndromes (22) · Leukemia, Lymphocytic, Chronic, B-Cell (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (20) · Leukemia, Myeloid, Acute (18) · Lymphoma, Mantle-Cell (16) · Leukemia (13) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (13) · Lymphoma, B-Cell (12) · Lymphoma, Follicular (12) · Hematologic Neoplasms (11) · Neoplasms (10)
Hemic and Lymphatic Diseases (172) · Immune System Diseases (172) · Immunoproliferative Disorders (172) · Lymphatic Diseases (172) · Neoplasms by Histologic Type (172) · Lymphoproliferative Disorders (171) · Neoplasms (162) · Lymphoma (133) · Hematologic Diseases (55) · Pathologic Processes (37) · Pathological Conditions, Signs and Symptoms (37) · Disease Attributes (35) · Leukemia, Lymphoid (30) · Chronic Disease (28) · Hemorrhagic Disorders (28)
Rituximab (48) · Cyclophosphamide (19) · Etoposide (13) · fludarabine (12) · Bendamustine Hydrochloride (10) · Melphalan (10) · Filgrastim (9) · fludarabine phosphate (9) · Vincristine (8) · Bortezomib (7) · Tacrolimus (7) · Whole-Body Irradiation (7) · Busulfan (6) · Prednisone (6) · Carmustine (5)
Hoffmann-La Roche (9) · Memorial Sloan Kettering Cancer Center (8) · Amgen (7) · Dana-Farber Cancer Institute (5) · Gilead Sciences (5) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (5) · Weill Medical College of Cornell University (5) · Massachusetts General Hospital (4) · National Cancer Institute (NCI) (4) · University of Southern California (4) · Asan Medical Center (3) · Astellas Pharma Inc (3) · Genentech, Inc. (3) · Masonic Cancer Center, University of Minnesota (3) · Pharmacyclics LLC. (3)
United States (119) · Canada (10) · France (10) · Italy (10) · Australia (9) · China (8) · Germany (8) · Spain (8) · South Korea (7) · United Kingdom (7) · Belgium (4) · Israel (4) · Poland (4) · Taiwan (4) · Japan (3)
Cheolwon Suh, MD, PhD (3) · Andrew Spencer, Assoc. Prof (2) · Anil Tulpule, MD (2) · Ann-Lii Cheng, Ph.D. (2) · Corey Cutler, MD, MPH (2) · Dolores Grosso, DNP, CRNP (2) · John P Leonard, MD (2) · Neal Flomenberg, MD (2) · Patrick Stiff, MD (2) · William Wegener, MD, PhD (2) · Abraham Kanate, MD (1) · Agha Mounzer, MD (1)
PMID 19451441, PMID 12907446, PMID 18268285, PMID 18839172, PMID 18997171, PMID 19018755, PMID 19547918, PMID 19706886, PMID 20107229, PMID 20235190, PMID 20626754, PMID 21239695, PMID 22198152, PMID 22438256, PMID 23990665, PMID 24048792, PMID 24761968, PMID 24827808, PMID 24911148, PMID 25204639, PMID 25404094, PMID 25482239, PMID 25568347, PMID 25665464, PMID 25909710, PMID 26282650, PMID 26687959, PMID 27269947, PMID 27339738, PMID 29437592, PMID 29477778, PMID 30890544, PMID 31050355, PMID 31196847, PMID 31573746, PMID 32209572, PMID 33072399, PMID 33236943, PMID 33586581, PMID 33739857, PMID 33741670, PMID 33766105, PMID 34510361, PMID 34941996, PMID 34953862, PMID 36507690, PMID 36601119, PMID 38271621, PMID 39365960, PMID 40156952
2015 (2), 2004 (1), 2014 (1), 2016 (1), 2018 (1), 2023 (1)